Leqembi

Concerns Arise Over Alzheimer’s Drug Leqembi Amid Linked Deaths

2 days ago

The recent surge in the use of the Alzheimer’s medication, Leqembi, has sparked serious concerns following reports of fatalities associated with its use. This controversial drug, which was initially celebrated for its potential benefits in combating Alzheimer’s disease, has now become the center of a heated debate about its safety and who should be eligible to receive it. Recent studies have revealed alarming data suggesting that patients receiving Leqembi in certain contexts may be at an increased risk of death, raising questions regarding its approval and distribution criteria.

Biogen Surpasses Earnings Expectations Thanks to Alzheimer’s Drug Leqembi

2 months ago

Biogen has delivered an impressive financial performance, exceeding Wall Street's projections for the fourth quarter, primarily driven by the strong sales of its Alzheimer’s treatment, Leqembi. The company reported quarterly sales that not only surpassed analyst forecasts but also indicated a significant resurgence in demand for its pharmaceutical offerings.

Biogen Boosts Forecast as Leqembi Shows Promising Growth in Alzheimer's Treatment

5 months ago

In a significant development for the biopharmaceutical sector, Biogen Inc. has raised its financial projections for the upcoming periods due to the encouraging performance of its Alzheimer's treatment, Leqembi. The announcement came on the heels of a third-quarter earnings report, which revealed that the drug has started to gain traction in the market, signaling potential advancement in Biogen’s business trajectory amidst ongoing challenges in the healthcare industry.